Breaking News
Get 40% Off 0
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance Find Stocks Now
Close

Innovent Biologics Inc (1801)

Create Alert
New!
Create Alert
Website
  • As an alert notification
  • To use this feature, make sure you are signed-in to your account
Mobile App
  • To use this feature, make sure you are signed-in to your account
  • Make sure you are signed-in with the same user profile

Condition

Frequency

Once
%

Frequency

Frequency

Delivery Method

Status

Add to/Remove from Watchlist Add to Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
38.15 +2.00    +5.53%
04:08:14 - Closed. Currency in HKD ( Disclaimer )
Type:  Equity
Market:  Hong Kong
ISIN:  KYG4818G1010 
  • Volume: 9,468,453
  • Bid/Ask: 38.10 / 38.15
  • Day's Range: 35.90 - 38.50
Innovent Biologics 38.15 +2.00 +5.53%

Innovent Biologics Inc Company Profile

 
Get an in-depth profile of Innovent Biologics Inc, including a general overview of the company's business and key management, as well as employee data and location and contact information.
IndustryPharmaceuticals
SectorHealthcare
Employees

5294

Equity Type

ORD

Innovent Biologics, Inc., a biopharmaceutical company, develops and commercializes monoclonal antibodies and other drug assets in the fields of oncology, ophthalmology, autoimmune, and cardiovascular and metabolic diseases in the People’s Republic of China. It offers Tyvyt, a human anti-PD-1 monoclonal antibody; BYVASDA, a fully-human anti-VEGF monoclonal antibody; HALPRYZA, a recombinant chimeric murine/human anti-CD20 monoclonal antibody; SULINNO, a fully-human antiTNF-a monoclonal antibody; Pemazyre, a selective FGFR inhibitor; Olverembatinib, a novel BCR-ABL TK; Cyramza, a VEGF receptor 2 antagonist; and Retsevmo, a selective and potent RET kinase inhibitor. The company is also developing IBI-326, a fully-human BCMA CAR T-cell therapy; IBI-376, an oral inhibitor of PI3Kd; IBI-351, a KRASG12C inhibitor; IBI-344, a repressor of silencing 1/TRK tyrosine kinase inhibitor; IBI-126, an ADC targeting CEACAM5; IBI-306, a novel anti-proprotein convertase subtilisin/kexin type 9 enzyme monoclonal antibody; IBI-362, a glucagon-like peptide-1 receptor/glucagon receptor dual agonist; and IBI-112, a novel long-acting anti-IL-23. In addition, it develops IBI-110, a novel anti-LAG3 monoclonal antibody; IBI-939, a novel anti-TIGIT monoclonal antibody; IBI-310, an anti-CTLA-4 monoclonal antibody; IBI-323, a novel LAG3/PD-L1 bispecific antibody; IBI-363, a potential PD-1/IL-2 bispecific antibody fusion protein; IBI-343, a recombinant anti-CLDN18.2 monoclonal ADC; and IBI-302, a potential anti-VEGF/complement bispecific fusion protein. Further, the company develops IBI-128, a late-stage novel non-purine xanthine oxidase inhibitor; IBI-353, a potent and selective, nextgeneration PDE4 inhibitor; and IBI-311, a recombinant anti-IGF-1R monoclonal antibody. Additionally, it distributes pharmaceutical products; and provides consultation, and research and development services. Innovent Biologics, Inc. was incorporated in 2011 and is headquartered in Suzhou, the People’s Republic of China.

Contact Information

Address 168 Dongping Street Suzhou Industrial Park
Suzhou, 215123
China
Phone 86 512 6956 6088
Fax 86 512 6956 6088

Top Executives

Name Age Since Title
De-Chao Yu 58 2011 Co-Founder, Chairman & CEO
Kai-Xian Chen 75 2018 Independent Non-Executive Director
Erwin Vanhaecke - - Member of CMC Strategic Advisory Board
Charles Leland Cooney 78 2015 Member of CMC Strategic Advisory Board & Independent Non-Executive Director
David LaPre - - Member of CMC Strategic Advisory Board
Chiang Syin 66 - Member of CMC Strategic Advisory Board
Carlos Garcia-Echeverria 57 2021 Member of Scientific Advisory Board
Lewis L. Lanier - 2021 Member of Scientific Advisory Board
Lawrence Fong - 2021 Member of Scientific Advisory Board
Gary J. Zieziula 67 2022 Independent Non-executive Director
I-Yin Hsu 48 2018 Independent Non-Executive Director
Hao Xi Ede 65 2024 Executive Director & Fund Managing Partner
Shun Lu - 2024 Independent Non-Executive Director
Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

1801 Comments

Write your thoughts about Innovent Biologics Inc
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
JAME Megueni
VRAQ Feb 13, 2022 9:33PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
*M Stanley Trims INNOVENT BIO TP to $65, Rated Overweight
JAME Megueni
VRAQ Jan 24, 2022 9:00PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
UBS Axes INNOVENT BIO TP to $65, Rated Buy
JAME Megueni
VRAQ Jan 20, 2022 8:45PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
*HSBC Global Research Cuts INNOVENT BIO TP to $85, Rated Buy
JAME Megueni
VRAQ Aug 29, 2021 11:30PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
C Suisse Cuts INNOVENT BIO TP to $90; Rated Outperform
JAME Megueni
VRAQ Aug 23, 2021 12:09AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
M Stanley Assumes INNOVENT BIO Shr Hike in 15 Days; Rated Overweight
JAME Megueni
VRAQ Apr 28, 2021 4:04AM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Daiwa Sees INNOVENT BIO as Sector Top-pick; 1Q Sintilimab Sales In Line
JAME Megueni
VRAQ Mar 07, 2021 9:42PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
UBS Lifts INNOVENT BIO TP to $132.9, Downgrades INNOCARE-B (09969.HK) to ***Neutral*** (Correct)
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email